Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
- PMID: 40242775
- PMCID: PMC12000078
- DOI: 10.3389/fimmu.2025.1572821
Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
Abstract
The intricate interaction between skeletal muscle biomechanics, the tumor microenvironment, and immunotherapy constitutes a pivotal research focus oncology. This work provides a comprehensive review of methodologies for evaluating skeletal muscle biomechanics, including handheld dynamometry, advanced imaging techniques, electrical impedance myography, elastography, and single-fiber experiments to assess muscle quality and performance. Furthermore, it elucidates the mechanisms, applications, and limitations of various immunotherapy modalities, including immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and combined chemoimmunotherapy, while examining their effects on skeletal muscle function and systemic immune responses. Key findings indicate that although immunotherapy is effective in augmenting antitumor immunity, it frequently induces muscle-related adverse effects such as weakness, fatigue, or damage, primarily mediated by cytokine release and immune activation. This work underscores the significance of immune niches within the tumor microenvironment in influencing treatment outcomes and proposes strategies to optimize therapy through personalized regimens and combinatorial approaches. This review highlights the need for further research on the formation of immune niches and interactions muscle-tumor. Our work is crucial for advancing the efficacy of immunotherapy, reducing adverse effects, and ultimately improving survival rates and quality of life of patients with cancer.
Keywords: immune checkpoint inhibitors; immune niches; immunotherapy; skeletal muscle biomechanics; tumor microenvironment.
Copyright © 2025 Ma, Lu, Sui, Yang, Fu, Tan, Chai, Lv, Kong, Wu, Gao and Yan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy.Front Immunol. 2025 May 2;16:1580108. doi: 10.3389/fimmu.2025.1580108. eCollection 2025. Front Immunol. 2025. PMID: 40386783 Free PMC article. Review.
-
Advances in research on flavonoids in tumor immunotherapy (Review).Mol Med Rep. 2025 Jun;31(6):150. doi: 10.3892/mmr.2025.13515. Epub 2025 Apr 11. Mol Med Rep. 2025. PMID: 40211703 Free PMC article. Review.
-
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.Gut Microbes. 2025 Dec;17(1):2452277. doi: 10.1080/19490976.2025.2452277. Epub 2025 Jan 18. Gut Microbes. 2025. PMID: 39826104 Review.
-
Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy.Cancer Immunol Immunother. 2025 Feb 4;74(3):100. doi: 10.1007/s00262-025-03944-1. Cancer Immunol Immunother. 2025. PMID: 39904769 Free PMC article. Review.
-
Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.Cancer Lett. 2021 Jul 28;511:68-76. doi: 10.1016/j.canlet.2021.04.021. Epub 2021 May 3. Cancer Lett. 2021. PMID: 33957184
Cited by
-
Impact of postoperative depression and immune-inflammatory biomarkers on the prognosis of patients with esophageal cancer receiving minimally invasive esophagectomy: a retrospective cohort study based on a Chinese population.Front Immunol. 2025 Jun 6;16:1610267. doi: 10.3389/fimmu.2025.1610267. eCollection 2025. Front Immunol. 2025. PMID: 40547019 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical